

# **Product Safety Data Sheet**

Document Code:	D0285534	Version :	1.0
Description:	MUCINEX ADULT COLD & SINUS LIQ	Status:	Published
Project Name:	Mercury	Project Number :	GU+APAP+PE
Category:	Cough	Segme nt:	Multi-Symptom Cough
Formula Type:	FILL FORMULA		

PSDS

**PSDS** 

ALL FORMULATIONS OF RECKITT BENCKISER HOUSEHOLD AND TOILETRY, PHARMACEUTICAL AND INDUSTRIAL PRODUCTS ARE PROPRIETARY, WHERE ADVICE IS AVAILABLE TO MEDICAL PRACTITIONERS ONLY.

\_\_\_\_\_

IN CASE OF EMERGENCY, CONTACT A MEDICAL PRACTITIONER OR Healthcare North America Inc.

Reckitt Benckiser

Emergency Contact: 1-866-MUCINEX (1-866-682-4639) (USA) AND ASK FOR THE MEDICAL INFORMATION UNIT .

Material Name: Maximum Strength Mucinex Fast Max Cold & Sinus Liquid

# 1. PRODUCT AND COMPANY IDENTIFICATION

**Product Use:** Relieves chest congestion by making cough productive (expectorant); reduces fever and pain (analgesi nasal congestion and relieve sinus pressure (nasal decongestant).

Manufactured for: Reckitt Benckiser LLC, Morris Corporate Centre IV, 399 Interspace Parkway (P.O. Box 225), Parsippany, New Jers USA

Emergency Telephone: 1-866-MUCINEX (1-866-682-4639) (USA)

# 2. COMPOSITION

Mucinex Cold & Sinus (Maximum Strength) Liquid: Each 20 mL of liquid contains Paracteamol (BP) or Acetaminophen (USP) 650 mg + Guaifenes Phenylephrine Hydrochloride 10 mg.

CAS#	Component
93-14-1	1,2-Propanediol, 3-(2-methoxyphenoxy)- (Guaifenesin)
61-76-1	(R)-m-Hydroxy-α-(methylaminomethyl-benzylalcohol) Phenylephrine hydrochloride

50-70-4 D-Glucitol (Sorbitol)
56-81-5 Glycerol (Glycerin)
57-55-6 1,2-Propylene glycol
50-99-7 Sucralose
77-92-9 Citric acid
103-90-2 Paracetamol, BP; Acetaminophen, USP

### 3. HAZARDS IDENTIFICATION

**Emergency Overview:** No hazards anticipated under normal product use conditions.

Potential Health Effects - Eyes: None anticipated under normal product use conditions. Potential Health Effects - Skin: None anticipated under normal product use conditions.

Potential Health Effects - Ingestion: None anticipated under normal product use conditions. Avoid occupational ingestion.

Potential Health Effects - Inhalation: None anticipated under normal product use conditions.

HMIS Ratings: Health: 1 Fire: 0 HMIS Reactivity 0

Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate 3 = Serious 4 = Severe \* = Chronic hazard

# Guaifenesin

Gastro-intestinal discomfort has occasionally been reported for guaifenesin. Very large doses cause nausea and vomiting.

#### 4. FIRST-AID MEASURES

First Aid - Eyes: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

First Aid - Skin: In the event of occupational skin contact, wash contaminated area thoroughly

First Aid - Ingestion: In the event of occupational ingestion, seek medical advice. Induction of vomiting is not a recommended first-aid procedure.

First Aid - Inhalation: Move person to non-contaminated air. Call a physician if symptoms develop or persist.

#### 5. FIRE-FIGHTING MEASURES

**General Fire Hazards:** See Section 9 for Flammability Properties. None anticipated

Hazardous Combustion Products : Not determined

Extinguishing Media: Use extinguishing media suitable for surrounding fire.

Fire Fighting Equipment/Instructions: Firefighters should wear full protective gear.

NFPA Ratings: Health: 1 Fire: 0 Reactivity: 0

Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate 3 = Serious 4 = Severe

# **6. ACCIDENTAL RELEASE MEASURES**

Containment Procedures: Containment of this material should not be necessary.
Clean-Up Procedures: Clean up residual material by washing area with water.
Evacuation Procedures: Isolate area. Keep unnecessary personnel away.

**Special Procedures:** None necessary.

# 7. HANDLING AND STORAGE

Handling Procedures: Avoid contact with skin and eyes.

Storage Procedures: No storage requirements necessary for occupational hazards. Follow storage recommendations for the product.

The following requirements are in place for shipping and distribution (they may be different to those on the pack which provide guidance for long to consumer):

Protect from direct sunlight. Long term average storage temperature should not exceed 30 °C and do not store below 15 °C. The following excursions

60 °C - Not permitted

50 °C - Not permitted

40 °C - Not more than 4 weeks

The excursions are not cumulative

### 8. EXPOSURE CONTROL AND PERSONAL PROTECTION

A: General Product Information - General mechanical ventilation is adequate for normal use. Local exhaust is recommended for confined areas. B: Component Exposure Limits - Glycerin (56-81-5)

ACGIH:	10 mg/m3 TWA
OSHA:	10 mg/m3 TWA (total dust); 5 mg/m3 TWA (respirable fraction)

# **Engineering Controls**

### PERSONAL PROTECTIVE EQUIPMENT

Personal Protective Equipment: Eyes/Face Personal Protective Equipment: Skin Personal Protective Equipment: Respiratory Personal Protective Equipment: General Personal Protective Equipment: General -

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Blue Colour Odor: Pleasant Physical State: Liquid pH: ND Vapor Pressure: ND Vapor Density: ND **Boiling Point:** ND Melting Point: ND Specific Gravity: Solubility (H2O): ND ND Evaporation Rate: ND VOC: ND Octanol/H2O Coeff.: ND Flash Point: ND ND Upper Flammability Limit (UFL): ND Flash Point Method: **Burning Rate:** Lower Flammability Limit (LFL): ND ND

Auto Ignition: ND

# 10. CHEMICAL STABILITY & REACTIVITY INFORMATION

# **Chemical Stability**

This is a stable material.

Chemical Stability: Conditions to Avoid None for normal handling of this product.

Incompatibility

None

**Hazardous Decomposition** 

Not Determined

Possibility of Hazardous Reactions

Will not occur.

# 11. TOXICOLOGY INFORMATION

### **Acute Dose Effects**

# A: General Product Information

No information available for the product.

### B: Component Analysis - LD50

**Citric acid (77-92-9)**Oral LD50 Rat: 3000 mg/kg

# Glycerin (Glycerol) (56-81-5)

Inhalation LC50 Rat: >570 mg/m3/1H; Oral LD50 Rat:12600 mg/kg; Dermal LD50 Rat:>21900 mg/kg

# Guaifenesin (93-14-1)

Oral LD50 Rat: 1510 mg/kg

# Paracetamol (UK) or Acetaminophen (USA) (103-90-2)

Oral Rat LD50: 2404 mg/kg IPR-Rat LD50: 1205 mg/kg IPR-Mouse LD50: 367 mg/kg

# Propylene glycol (57-55-6)

Oral LD50 Rat: 20000 mg/kg; Dermal LD50 Rabbit:20800 mg/kg

# Sorbitol (50-70-4)

Oral LD50 Rat (IV) 29,600 mg/kg Oral LD50 mouse: 17,800 mg/kg

### Sucralose (56038-13-2)

Oral LD50 Rat: >10,000 mg/kg Oral LD50 mouse: >16,000 mg/kg

### Carcinogenicity

### A: General Product Information

No information available for the product.

# **B: Component Carcinogenicity**

None of this product's components are listed by ACGIH, IARC, OSHA, NIOSH, or NTP.

# 12. ECOLOGICAL INFORMATION

#### **Ecotoxicity**

#### A: General Product Information

No data available for this product.

# B: Component Analysis - Ecotoxicity - Aquatic Toxicity

# Glycerin (56-81-5)

Test & Species		Conditions
96 Hr LC50 Oncorhynchus mykiss	51000-57000 mg/L	
24 Hr EC50 Daphnia magna	>500 mg/L	

# Propylene glycol (57-55-6)

Test & Species		Conditions
96 Hr LC50 Oncorhynchus mykiss	51600 mg/L [static]	
96 Hr LC50 Pimephales promelas	51400 mg/L [static]	
96 Hr EC50 Selenastrum capricornutum	19000 mg/L	
30 min EC50 Photobacterium	710 mg/L	
phosphoreum		
48 Hr EC50 water flea	>10000 mg/L	

# Citric acid (77-92-9)

Test & Species		Conditions
96 Hr LC50 Lepomis macrochirus	1516 mg/L [static]	
96 Hr LC50 Leuciscus idus	440 mg/L [static]	
15 min EC50 Photobacterium	14 mg/L	
phosphoreum		
72 Hr EC50 Daphnia magna	120 mg/L	

# 13. DISPOSAL CONSIDERATION

# **US EPA Waste Number & Descriptions**

# **Component Waste Numbers**

No EPA Waste Numbers are applicable for this product's components.

### **Disposal Instructions**

All wastes must be handled in accordance with local, state and federal regulations.

See Section 7 for Handling Procedures. See Section 8 for Personal Protective Equipment recommendations.

#### 14. TRANSPORTATION INFORMATION

### **US DOT Information**

Shipping Name: Not Regulated

# 15. REGULATORY INFORMATION

### **US Federal Regulations**

# **Component Analysis**

None of this products components are listed under SARA Section 302 (40 CFR 355 Appendix A), SARA Section 313 (40 CFR 372.65), or CERCLA (4 State Regulations

#### Component Analysis - State

The following components appear on one or more of the following state hazardous substances lists:

Component	CAS	CA	M	М	NJ	PA	RI
			l A	N			
Glycerin	56-81-5	No	Ye	Ye	No	Ye	Ye
			s	S		S	S
Propylene glycol	57-55-6	No	No	Ye	No	Ye	Ye
		1	I	s		s	S

## Component Analysis - WHMIS IDL

The following components are identified under the Canadian Hazardous Products Act Ingredient Disclosure List:

Component	CAS#	Minimum Concentration
Propylene glycol	57-55-6	1 %
Citric acid	77-92-9	1 %

# Additional Regulatory Information

# Component Analysis - Inventory

Component	CAS#	TSCA	CAN
Phenlephrine Hydrochloride, USP	61-76-1	Yes	DSL
D-Glucitol (Sorbitol)	50-70-4	Yes	DSL
Glycerin (Glycerol)	56-81-5	Yes	DSL
Propylene glycol	57-55-6	Yes	DSL
Guaifenesin, USP	93-14-1	Yes	DSL
Citric Acid	77-92-9	Yes	DSL
Acetaminophen, USP	103-90-2	Yes	DSL

# **16. OTHER INFORMATION**

# Other Information

The information herein is presented in good faith and believed to be accurate as of the effective date given. However, no warranty, expressed or implitute buyer's responsibility to ensure that its activities comply with Federal, State or provincial and local laws.

# Key/Legend

EPA = Environmental Protection Agency; TSCA = Toxic Substance Control Act; ACGIH = American Conference of Governmental Industrial Hygienist International Agency for Research on Cancer; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; O Occupational Safety and Health Administration, NJTSR = New Jersey Trade Secret Registry.

## Where Used

Where Used

Customer Product Bill of Material

0326655 : FIL,MUCNX,ADLT CLD&SI LIQ(ALT)
0285475 : FIL,MUCNX,ADLT COLD& SINUS LIQ

# History

Document History (Ver. 1.0)		
Author:	Venkatesh Balasubramanian/AANZ/R_B	
Co-Author:	Jeannie Wong/AANZ/R_B	
Creation Date:	09 Nov 2010 13:55 GMT	
Creation Reason:	New Document. Mucinex 2011	
Approved By Regulatory:	Douglas Flint/AANZ/R_B	16 Feb 2011 16:36 GMT
Published Date:	16 Feb 2011 23:54 GMT	

This document is only current on the day of viewing. Printed copies are UNCONTROLLED unless they are part of a Quality/Technical Manual or attached referring to a Purchase Order Number. END OF DOCUMENT